This Event Has Now Run
Thank you to our speakers, sponsors, and delegates who joined us in Boston! If you are interested in the 2026 event, please get in touch at: info@hansonwade.com
Accelerating the Discovery, Development & Approval of First-In-Class Selective, Safe & Efficacious Degraders & Proximity-Based Drugs to Target the Undruggable
As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 was poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.
Returning as the industry’s definitive forum from early discovery to clinical development, the Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.
2025 Summit featured key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this was your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.
Attending Companies Included